Sophia Le
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sophia Le has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Anthony Ndyanabo
Rakai Health Sciences Program, Kalisizo, Uganda
1 shared publicationChun-Mien Chang
1 shared publicationDeo Okedi
AirQo, Department of Computer Science, Makerere University, Kampala, Uganda
1 shared publication- Deo Okure
AirQo, Department of Computer Science, Makerere University, Kampala, Uganda
1 shared publication Dong-Won Lee
Environmental Satellite Centre, Climate and Air Quality Research Department, National Institute of Environmental Research, Incheon, 22689, South Korea
1 shared publication- Elizabeth Hernandez
Médico Cirujano. Especialista en Anestesiología y Medicina Crítica. Adjunto del Servicio de Anestesiología del Hospital “Dr. Domingo Guzmán Lander”
1 shared publication
Latest Publications
- Open Access
- 16 May 2025
- Published by Elsevier in Atmospheric Pollution Research
- Vol. 16 (9)
Calibration of low-cost sensor data for ambient PM2.5 monitoring across urban and rural settings in South Central Uganda
- 16 May 2025
- Published by Elsevier in Atmospheric Pollution Research
- Vol. 16 (9)
Open AccessCalibration of low-cost sensor data for ambient PM2.5 monitoring across urban and rural settings in South Central Uganda
- Open Access
- 1 January 2021
- Published by Elsevier in Environmental Pollution
- Vol. 269, 115924
Assessment of long-range transboundary aerosols in Seoul, South Korea from Geostationary Ocean Color Imager (GOCI) and ground-based observations
- 1 January 2021
- Published by Elsevier in Environmental Pollution
- Vol. 269, 115924
Open AccessAssessment of long-range transboundary aerosols in Seoul, South Korea from Geostationary Ocean Color Imager (GOCI) and ground-based observations
- 1 May 2020
- Published by American Scientific Publishers in Journal of Biomedical Nanotechnology
- Vol. 16 (5) , 583-593
Anticancer Efficacy of Oral Docetaxel Nanoformulation for Metronomic Chemotherapy in Metastatic Lung Cancer
Metronomic chemotherapy, giving low doses of chemotherapeutics (e.g., docetaxel) on a frequent schedule over a long time, may improve outcomes and reduce side effects for cancer patients. Oral medications are vital for applying metronomic chemotherapy. However, low solubility, low absorption, low drug availability in the targeted tissue, and side effects limit the development of oral chemotherapeutics. Many chemotherapeutics are intravenously delivered. In this work, we developed a new docetaxel granule that produces docetaxel-loaded in situ self-assembled nanoparticle (180 nm) upon contact with water. The process of manufacturing docetaxel granules is scalable in industrial settings. The lung selectivity of docetaxel granule was observed in animals. The mechanistic studies demonstrated the nanoparticle bound with red blood cells, which selectively delivers docetaxel to the lungs. Finally, docetaxel granule (5 mg/kg twice per week) can profoundly inhibit the tumor growth of lung-metastatic cancer xenograft model over 24 days. The material-based lungselective oral nanoformulation provides an opportunity for conventionally intravenous chemotherapy drugs to be easily applied in oral administration for metronomic chemotherapy for cancer patients with lung cancers.
- 1 May 2020
- Published by American Scientific Publishers in Journal of Biomedical Nanotechnology
- Vol. 16 (5) , 583-593
Anticancer Efficacy of Oral Docetaxel Nanoformulation for Metronomic Chemotherapy in Metastatic Lung Cancer
Metronomic chemotherapy, giving low doses of chemotherapeutics (e.g., docetaxel) on a frequent schedule over a long time, may improve outcomes and reduce side effects for cancer patients. Oral medications are vital for applying metronomic chemotherapy. However, low solubility, low absorption, low drug availability in the targeted tissue, and side effects limit the development of oral chemotherapeutics. Many chemotherapeutics are intravenously delivered. In this work, we developed a new docetaxel granule that produces docetaxel-loaded in situ self-assembled nanoparticle (180 nm) upon contact with water. The process of manufacturing docetaxel granules is scalable in industrial settings. The lung selectivity of docetaxel granule was observed in animals. The mechanistic studies demonstrated the nanoparticle bound with red blood cells, which selectively delivers docetaxel to the lungs. Finally, docetaxel granule (5 mg/kg twice per week) can profoundly inhibit the tumor growth of lung-metastatic cancer xenograft model over 24 days. The material-based lungselective oral nanoformulation provides an opportunity for conventionally intravenous chemotherapy drugs to be easily applied in oral administration for metronomic chemotherapy for cancer patients with lung cancers.